Evidence map›Paper›PMID 28324233›Full record

ReviewAmerican journal of clinical dermatology2017

Diagnosis and Treatment of Kaposi Sarcoma.

Johann W Schneider, Dirk P Dittmer

Open access · greenAbstract readReview
In one paragraph

Review in American journal of clinical dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. World journal of gastroenterology · 2019
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Incidence, screening, and management ofWorld journal of transplantation · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.Frontiers in cell and developmental biology · 2025
    Review
  19. Kaposi Sarcoma: A Case of Mistaken Identity in an Immunocompetent Healthy Male.European journal of case reports in internal medicine · 2025
    Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Johann W SchneiderNational Health Laboratory Service, Division of Anatomical Pathology, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa. jws2@sun.ac.za.
Dirk P DittmerDepartment of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB#7295, 450 West Dr., Chapel Hill, NC, 27517, USA. ddittmer@med.unc.edu.
Tygerberg Hospital · ZAUniversity of North Carolina at Chapel Hill · US

Funding

Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
AIDS and Cancer Specimen Resource (ACSR)UM1CA181255 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeffrey Michael Bethony, Anna Coghill · 2013 to 2026
$56.7M
University of Southern CaliforniaU01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SPARANO, JOSEPH A. · 2006 to 2014
$54.7M
ART Modulation of Viral Pathogenesis in Oral EpitheliaR01DE018304 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2007 to 2025
$6.9M
Project 3U54CA190152 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A, GOPAL, SATISH · 2014 to 2019
$4.2M
Origin and Lineage of Differentiation of Kaposi's SarcomaR21CA192744 · NCI · STELLENBOSCH UNIVERSITY · PI DITTMER, DIRK P, SCHNEIDER, JOHANN WILHELM · 2015 to 2016
$346k
NCI NIH HHS R21 CA192744NCI NIH HHS U01 CA121947NCI NIH HHS U54 CA190152NCI NIH HHS UM1 CA121947NCI NIH HHS UM1 CA181255NIDCR NIH HHS R01 DE018304
6 · The paper itself

Abstract

Kaposi sarcoma (KS) is the most common neoplasm of people living with HIV today. In Sub-Saharan Africa, KS is among the most common cancers in men, overall. Not only HIV-positive individuals present with KS; any immune compromised person infected with KS-associated herpesvirus (KSHV) or human herpesvirus 8 is at risk: the elderly, children in KSHV-endemic areas, and transplant recipients. KS diagnosis is based on detection of the viral protein latency-associated nuclear antigen (LANA) in the biopsy, but not all cases of KS are the same or will respond to the same therapy. Standard KS therapy has not changed in 20 years, but newer modalities are on the horizon and will be discussed.

Indexed as

Immunocompromised HostAntineoplastic AgentsEarly DiagnosisHerpesviridae InfectionsHerpesvirus 8, HumanHIV InfectionsHumansIncidenceRisk FactorsSarcoma, KaposiTreatment OutcomeUnited StatesVascular Endothelial Growth Factor AAntineoplastic AgentsVascular Endothelial Growth Factor A

Identifiers

PMID28324233
PMCPMC5509489
OpenAlexW2598076133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.